| United States Patent | 5,510,485 |
| Graham, et. al. | Apr. 23, 1996 |
17-ester, amide, and ketone derivatives of 3-oxo-4-azasteroids as 5A-reductase inhibitors
| Inventors: | Graham; Donald W. (Mountainside, NJ); Aster; Susan D. (Teaneck, NJ); Hagmann; William (Westfield, NJ); Tolman; Richard L. (Warren, NJ). |
| Assignee: | Merck & Co., Inc. (Rahway, NJ). |
| Appl. No.: | 335,792 |
| Filed: | Nov. 10, 1994 |
Related U.S. Application Data
| Continuation-in-part of Ser No. 886,021, May 20, 1992, abandoned. |
| Intl. Cl. : | C07D 241/12, A61K 31/495 |
| Current U.S. Cl.: | 544/336; 544/405; 544/406; 546/77 |
| Field of Search: | 546/77; 514/284, 253; 544/336 |
References Cited | [Referenced By:]
U.S. Patent Documents
| 4,377,584 | Mar., 1983 | Rasmusson | 514/284 |
| 4,732,897 | Mar., 1988 | Cainelli et al. | |
| 4,760,071 | Jul., 1988 | Rasmusson et al. | |
| 4,859,681 | Aug., 1989 | Rasmusson | 514/284 |
| 4,882,319 | Nov., 1989 | Holt | 514/119 |
| 4,888,336 | Dec., 1989 | Holt et al. | 546/77 |
| 5,049,562 | Sept., 1991 | Rasmusson et al. | 546/77 |
| 5,110,939 | May, 1992 | Holt | 548/250 |
| 5,116,983 | May, 1992 | Bhattacharya | 546/77 |
| 5,120,742 | Jun., 1992 | Rasmusson et al. | 514/284 |
| 5,138,063 | Aug., 1992 | Rasmusson et al. | |
| 5,175,155 | Dec., 1992 | Juniewicz et al. | 514/284 |
| 5,278,159 | Jan., 1994 | Bakshi et al. | |
| 5,300,294 | Apr., 1994 | Johnson | |
| 5,302,621 | Apr., 1994 | Kojima et al. |
Foreign Patent Documents
| 0200859 | Nov., 1986 | EP | |
| 93-23051 | Nov., 1993 | WO | |
| WO93/23420 | Nov., 1993 | WO |
- Other References
- Stinson, Chem. Eng. News, Jun. 29, ’92 pp. 7-8.Helliker, Wall Street Jour. 7 Jun. ’91, pp. A1 and A7 (1991).Diani et al., Jour. of Clin. & Metab. vol. 74 pp. 345-350 (1992).
Rasmusson et al. Jour Med Chem vol. 29 pp. 2298-2315 (1986).
Burger, “Medicinal Chemistry 2d Ed” Interscience N.Y., 1960 p. 42.
Rasmusson et al Jour Med Chem vol. 27 pp. 1690-1701 (1984).
Back, Jour Org Chem vol. 46 pp. 1442-1446 (1981).
Helliker, “Alopecia Sufferers Seek to Suffer Less, and Not in Silence”, Wall Street Journal, 7 Jun. 1991, pp. A1 and A7.
Burger, Medicinal Chem. 2nd Ed Interscience, N.Y. 1960, p. 42.
Geldof, “Consideration of the Use of 17-Beta-N,N-diethyl Carbamoyl-4-Methyl-4-Aza-5-Alpha-Androstan-3-one (4MA) A 5-Alpha Reductase Inhibitor, in Prostate Cancer Therapy”, J. Cancer Res. Clin. Oncol. 118:50-55 (1992).
Liang et al. “Species Differences in Prostatic Steroid 5alpha-reductases of Rat, Dog and Human”, Endocrinology, vol. 117, No. 2, pp. 571-579 (1985).
Rasmusson et al., “Azasteroids, Structure-Activity Relationships for Inhibition of 5-alpha Reductase and of Androgen Receptor Binding”, J. Med. Chem. 29: 2298-2315 (1986).
Back et al., “N-chloroazasteroids: A Novel Class of Reactive Steroid Analogous Preparation, Reaction with Thiols and Photochemical Conversion to Electrophilic N-acyl Imines”, J. Org. Chem. 54: 1904-1910 (1989).
Stinson, “Prostate Drug Proscar Cleared for Marketing”, Chem. Eng. News, 1992, pp. 7-8.
Diani et al., “Hair Growth Effects of Oral Administration of finasteride . . . “, Jour. Clinincal Endoc. & Metab. 74: 345-350 (1992).
Back, “Oxidation of Azasteroid Lactams and Alcohols with Benezene Selenic Anhydride”, J. Org. Chem. 46: 1442-1446 (1981).
Rasmusson et al., “Azasteroids as Inhibitors of Rat Prostate 5-alpha Reductase”, J. Med. Chem. 27: 1690-1701 (1984).
Primary Examiner: Daus; Donald G.
Attorney, Agent or Firm: Giesser; Joanne M., Fitch; Catherine D., Winokur; Melvin
Abstract
Described are new 17.beta.-ester, amide and ketone 4-aza-5a-androstan-3-ones and related compounds and their use as 5a-reductase inhibitors for treatment of benign prostatic hyperplasia and other hyperandrogenetic related disorders.
3 Claims, No Drawings
